TNGX Stock Overview
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Tango Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.70 |
52 Week High | US$13.03 |
52 Week Low | US$2.47 |
Beta | 0.90 |
1 Month Change | -32.28% |
3 Month Change | -25.60% |
1 Year Change | 91.54% |
3 Year Change | -30.76% |
5 Year Change | n/a |
Change since IPO | -24.73% |
Recent News & Updates
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%
Mar 19Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans
Mar 06Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk
Jan 08Recent updates
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%
Mar 19Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans
Mar 06Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk
Jan 08Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)
Aug 12Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?
May 10Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer
Oct 20Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth
Oct 05Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 13Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M
Aug 10We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn
May 28We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow
Jan 06Shareholder Returns
TNGX | US Biotechs | US Market | |
---|---|---|---|
7D | -9.4% | 0.9% | 0.4% |
1Y | 91.5% | 10.3% | 28.8% |
Return vs Industry: TNGX exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: TNGX exceeded the US Market which returned 29.5% over the past year.
Price Volatility
TNGX volatility | |
---|---|
TNGX Average Weekly Movement | 9.0% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TNGX's share price has been volatile over the past 3 months.
Volatility Over Time: TNGX's weekly volatility has decreased from 19% to 9% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 140 | Barbara Weber | https://www.tangotx.com |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers.
Tango Therapeutics, Inc. Fundamentals Summary
TNGX fundamental statistics | |
---|---|
Market cap | US$821.73m |
Earnings (TTM) | -US$101.74m |
Revenue (TTM) | US$36.53m |
22.5x
P/S Ratio-8.1x
P/E RatioIs TNGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TNGX income statement (TTM) | |
---|---|
Revenue | US$36.53m |
Cost of Revenue | US$115.20m |
Gross Profit | -US$78.67m |
Other Expenses | US$23.07m |
Earnings | -US$101.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.95 |
Gross Margin | -215.38% |
Net Profit Margin | -278.54% |
Debt/Equity Ratio | 0% |
How did TNGX perform over the long term?
See historical performance and comparison